drugset / Trial / NCT00856362

Study Evaluating The Co-Administration Of Moxidectin And Midazolam In Healthy Subjects

NCT00856362

Phase 1 Completed 38 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effect of single doses of midazolam on the plasma concentration of a single dose of moxidectin in healthy young adult subjects, and to assess the safety of co-administration of moxidectin and midazolam.

Timeline

Start
2009-04
Primary completion
2009-09
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Midazolam Small molecule
Subject Moxidectin Other / unclassified

Indications

No indication recorded.